



Ifu

PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number 10/575,348

Filing Date April 7, 2006

First Named Inventor BEZENCON et al.

Art Unit TBD

Examiner Name TBD

Attorney Docket Number AC-02-US

ENCLOSURES (Check all that apply)

<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance Communication to TC
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	--Form 1449 (3 pages)
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> CD, Number of CD(s) _____	--IDS Transmittal Letter (2 pages)
	<input type="checkbox"/> Landscape Table on CD	--Thirty-five (35) references
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	--Six (6) International Search Reports (18 pages)
<input type="checkbox"/> Reply to Missing Parts/ Incomplete Application	Other Enclosures (con't.)	
<input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	--Return-receipt postcard	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	HOXIE & TSO LLP		
Signature			
Printed name	Thomas Hoxie		
Date	July 14, 2006	Reg. No.	32,993

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below: a box			
Signature			
Typed or printed name	Michele Konrad	Date	July 14, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



S/N 10/575,348

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Bezencon et al.) Examiner: TBD
)
Serial No.: 10/575,348) Group Art Unit: TBD
)
Filed: April 7, 2006) Attorney Docket: AC-02-US
)
Title: Novel Tetrahydropyridine Derivatives)

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

In accordance with 37 C.F.R. §1.97 *et. seq.*, Applicant provides the enclosed materials for the Examiner's consideration in connection with the above-identified patent application.

Applicant respectfully requests that this First Supplemental Information Disclosure Statement and the documents listed on the attached Form 1449 and enclosed herewith be considered by the Examiner and made of record. Pursuant to the provisions of MPEP 609, Applicant requests that a copy of the 1449 form, initialed as being considered by the Examiner, be returned to the Applicant with the next official communication.

Copies of foreign and non-patent documents and communication from a foreign patent office are enclosed herein.


The information contained in this First Supplemental Information Disclosure Statement is not to be construed as a representation 1) that a search has been conducted; 2) that additional

information material to the examination of this application does not exist; 3) that the information, protocol, results and the like reported by third parties are accurate or enabling; 4) that the information is considered to be material to patentability; or 5) that the information constitutes prior art to the current application.

It is believed that no fee is required. If a fee is required, please charge the same to Deposit Account No. 50-3464. The Examiner is invited to contact the Applicant's representative at the telephone number listed below if there are any questions.


Respectfully submitted,

Date: July 14, 2006



Thomas Hoxie
Reg. No. 32,993
HOXIE & TSO LLP
374 Millburn Avenue
Suite 300E
Millburn, New Jersey 07041
973-467-2126

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)	Complete if Known	
	Application Number	10/575,348
	Filing Date	April 7, 2006
	First Named Inventor	BEZENCON, et al.
	Group Art Unit	TBD
	Examiner Name	TBD
Sheet 1 of 3	Attorney Docket No: AC-02-US	



US PATENT DOCUMENTS

Examiner Initial *	USP Document Number	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	10/575,794	Filed 04/12/2006	Bezencon et al.	
	10/576,904	Filed 04/21/2006	Bezencon et al.	
	10/581,829	Filed 06/02/2006	Bezencon et al.	
	10/581,824	Filed 06/02/2006	Bezencon et al.	
	10/554,879	Filed 10/28/2005	Bezencon et al.	
	5,703,073	12/30/1997	Garvey, D.S. et al.	
	5,380,758	01/10/1995	Stamler, J. et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Foreign Document No	Publication Date	Name of Patentee or Applicant of cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ²
	WO 01/00577 A2	01/04/2001	Rizzo, J. et al.		
	WO 99/00361	01/07/1999	Del Soldato, P.		
	WO 98/19672	05/14/1998	Garvey, D.S. et al.		
	WO 98/21193	05/22/1998	Del Soldato, P.		
	WO 98/39328	09/11/1998	Guerry, P. et al.		
	WO 97/27749	08/07/1997	Garvey, D.S. et al.		

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		LIZOTTE, K.E., et al. <i>Synthesis and Conformational Aspects of cis-and trans-3-Carbomethoxy-6-oxabicyclo[3.1.0]hexane</i> , J. Org. Chem., 1983, pages 3594-3597, Vol. 48, No. 20.	
		SHIGERU, O., et al. <i>Organic Thionitrites and related Substances. A Review.</i> , Organic Preparations and Procedures Int., 1983, pages 165-198, Vol. 15(3).	
		COMINS, D.L., et al. <i>Regiospecific alpha-Alkylation of 4-Chloro(bromo)pyridine</i> , J. Org. Chem., 1985, pages 4410-4411, Vol. 50, No. 22.	
		WERMUTH, C.G. <i>Molecular Variations Based on Isosteric Replacements, The Practice of Medicinal Chemistry</i> , 1996, pages 203-237.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/575,348
Filing Date	April 7, 2006
First Named Inventor	BEZENCON, et al.
Group Art Unit	TBD
Examiner Name	TBD



Sheet 2 of 3

Attorney Docket No: AC-02-US

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		JOHNSON, C.R., et al. <i>Libraries of N-Alkylaminoheterocycles from Nucleophilic Aromatic Substitution with Purification by Solid Supported Liquid Extraction</i> , Tetrahedron , 1998, pages 4097-4106, Vol. 54.	
		WEABER, B., et al. <i>The renin-angiotensin system: role in experimental and human hypertension</i> , Handbook of Hypertension , 1986, pages 489-519, Vol. 8.	
		WEBER, M.A. <i>Clinical Experience With the Angiotensin II Receptor Antagonist Losartan, A Preliminary Report</i> , American Journal of Hypertension , 1992, pages 247S-251S, Vol. 5, No. 12, Part 2.	
		ROSENBERG, M.E., et al. <i>The paradox of the renin-angiotensin system in chronic renal disease</i> , Kidney International , 1994, pages 403-410, Vol. 45.	
		BREYER, J.A., et al. <i>Angiotensin converting enzyme inhibition in diabetic nephropathy</i> , Kidney International , 1994, pages S156-S160, Vol. 45, Suppl. 45.	
		VAUGHAN, D.E., et al. <i>Angiotensin converting enzyme inhibitors and cardiovascular remodelling</i> , Cardiovascular Research , 1994, pages 159-165, Vol. 28.	
		FOUAD-TARAZI, F.M., et al. <i>The Renin-Angiotensin System and Treatment of Heart Failure</i> , American Journal of Medicine , 1988, pages 83-86, Vol. 84.	
		PFEFFER, M.A., et al. <i>Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction</i> , New England Journal of Medicine , 1992, pages 669-677, Vol. 327, No. 10.	
		KLEINERT, H.D. <i>Renin Inhibition</i> , Cardiovascular Drugs and Therapy , 1995, pages 645-655, Vol. 9.	
		HUSAIN, A. <i>The chymase-angiotensin system in humans</i> , Journal of Hypertension , 1993, pages 1155-1159, Vol. 11, No. 11.	
		ISRAILI, Z.H., et al. <i>Cough and Angioneurotic Edema Associated with Angiotensin-converting Enzyme Inhibitor Therapy, A Review of the Literature and Pathophysiology</i> , Annals of Internal Medicine , 1992, pages 234-242, Vol. 117, No. 3.	
		AZIZI, M., et al. <i>Blood pressure effects of acute intravenous renin or oral angiotensin converting enzyme inhibition in essential hypertension</i> , Journal of Hypertension , 1994, pages 419-427, Vol. 12, No. 4.	
		NEUTEL, J.M., et al. <i>Immediate blood pressure effects of the renin inhibitor enalkiren and the angiotensin-converting enzyme inhibitor enalaprilat</i> , American Heart Journal , 1991, pages 1094-1100, Vol. 122, No. 4, Part 1.	
		RAHUEL, J., et al. <i>Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin</i> , Chemistry & Biology , 2000, pages 493-504, Vol. 7, No. 7.	
		MEALY, N.E., et al. <i>Aliskiren Fumarate</i> , Drugs of the Future , 2001, pages 1139-1148, Vol. 26, No. 12.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.


Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/575,348
Filing Date	April 7, 2006
First Named Inventor	BEZENCON, et al.
Group Art Unit	TBD
Examiner Name	TBD



Sheet 3 of 3

Attorney Docket No: AC-02-US

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		OEFNER, C., et al. <i>Renin inhibition by substituted piperidines: a novel paradigm for the inhibition of monomeric aspartic proteinases?</i> , Chemistry & Biology , 1999, pages 127-131, Vol. 6, No. 3.	
		KIESEWETTER, D.O. <i>Asymmetric Synthesis of Benzilic Acid Analogues Using 8-Phenylmenthol as a Chiral Auxiliary</i> , Tetrahedron Asymmetry , 1993, pages 2183-2198, Vol. 4, No. 10.	
		VIEIRA, E., et al. <i>Substituted Piperidines – Highly Potent Renin Inhibitors due to Induced Fit Adaptation of the Active Site</i> , Bioorganic & Medicinal Chemistry Letters , 1999, pages 1397-1402, Vol. 9.	
		MARCH, J. Advanced Organic Chemistry , 3 rd Ed., John Wiley & Sons, 1985.	
		MAJEWSKI, M., et al. <i>Synthesis of Tropane Alkaloids via Enantioselective Deprotonation of Tropinone</i> , J. Org. Chem. , 1995, pages 5825-5830, Vol. 60, No. 18.	
		JERCHEL, D., et al. <i>N-Methyl-Oxa-Granatolin</i> , Justus Liebigs Ann. Chem. , 1957, pages 126-131, Vol. 607.	
		ZIRKLE, C.L., et al. <i>The Isomeric 3-Oxa- and 3-Thiagranatanin-7-ols and Their Derivatives; Reduction of Bicyclic Amino Ketones Related to Tropone</i> , J. Org. Chem. , 1961, pages 395-407, Vol. 26.	
		ANDERSON, W.K., et al. <i>Synthesis, Chemistry, and Antineoplastic Activity of α-Halopyridinium Salts: Potential Pyridone Prodrugs of Acylated Vinylogous Carbinolamine Tumor Inhibitors</i> , J. Med. Chem. , 1990, pages 1667-1675, Vol. 33, No. 6.	
		KRAFT, P. <i>Design and Synthesis of Violet Odorants with Bicyclo[6.4.0]dodecene and Bicyclo[5.4.0]undecene Skeletons</i> , Synthesis , 1999, pages 695-703, No. 4.	
		SCHNELL, C.R. et al. <i>Measurement of blood pressure and heart rate by telemetry in conscious, unrestrained marmosets</i> , Am. J. Physiol. 264 (Heart Circ. Physiol. 33), 1993, pages H1509-H1516.	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.¹ Applicant's unique citation designation number (optional) ² Applicant is to place a check mark here if English language Translation is attached